Swiss-based Galderma Group AG achieved $3.259 billion in net sales during the first nine months of 2024, up 9.2% year-on-year in constant currency, driven in part by volume growth, complemented by favorable mix. Its Q3 net sales also set a record, per Galderma.
Highlights included double-digit growth in injectable aesthetics (up 10.6%) and dermatological skin care (also up 10.6%) and therapeutic dermatology (up 2.9%).
In Q3 in particular, Galderma pursued a new retailer execution strategy, marketing revamp and digital-first activation for Cetaphil.
In that time, Cetaphil's Gentle Exfoliating line launched in the U.S. market, while the brand tapped Gen-Z influencer Katie Fang.
Meanwhile, Alastin expanded in Brazil and Colombia.
Galderma is expecting full-year net sales growth of 8.8-9.5% year-on-year at constant currency; the previous range was "expected towards the upper end of the 7-10% growth range."
